Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
August 19–September 1: The Viet Minh seizes control of Hanoi and much of the former Empire of Vietnam after the surrender of Japan, proclaiming the Democratic Republic of Vietnam and initiating civil conflicts. September 2: Surrender of Japan - The Empire of Japan surrenders unconditionally to the United States, officially ending World War II. General Douglas MacArthur presides over the occupation of Japan, and freezes out Russian and other allied representatives(V-J day). September 5: Igor Gouzenko, a Soviet agent working in the Soviet embassy in Canada, defects and provides proof to the Royal Canadian Mounted Police of a Soviet spy ring operating in Canada and the U.S. The revelations help change perceptions of the Soviet Union from an ally to a foe. October 25: Taiwan is transferred to the Republic of China from Japan. Initially the Chinese public was supportive of the transfer but later becomes less so as the newly appointed governor, General Chen Yi gains a reputation for being corrupt and mismanaging the island. Economic problems also occur as the governor extends the scope of the government monopoly over Taiwan's resources in order to sell these goods to the mainland to help fight the Communist forces. The conditions on the island later contribute to the February 28 incident. November: Iran crisis of 1946 - Stalin refuses to relinquish Soviet-occupied territory in Iran, beginning the Iran Crisis. Two short-lived pro-Soviet states, the Azerbaijan People's Government and the Republic of Mahabad, are formed. November 20: The Nuremberg trials begin.
An autograft may also be performed without a solid bony structure, for example, using bone reamed from the anterior superior iliac spine. In this case, there is an osteoinductive and osteogenic action, however, there is no osteoconductive action, as there is no solid bony structure. Chin offers a large amount of cortico-cancellous autograft and easy access among all the intraoral sites. It can be easily harvested in the office settings under local anaesthesia on an outpatient basis. Proximity of the donor and recipient sites reduce operative time and cost. Convenient surgical access, low morbidity, elimination of hospital stay, minimal donor site discomfort and avoidance of cutaneous scars are the added advantages.
San Francisco's progressive community tried to field a candidate to run against Newsom. Supervisors Ross Mirkarimi and Chris Daly considered running, but both declined. Gonzalez also decided not to challenge Newsom again. When the August 10, 2007, filing deadline passed, San Francisco's discussion shifted to talk about Newsom's second term. He was challenged in the election by 13 candidates, including George Davis, a nudist activist, and Michael Powers, owner of the Power Exchange sex club. Conservative former supervisor Tony Hall withdrew by early September due to lack of support. In August 2007, the San Francisco Chronicle wrote that Newsom faced no "serious threat to his re-election bid", having raised $1.6 million for his campaign by early August. He was reelected on November 6 with over 72% of the vote. Upon taking office for a second term, Newsom promised to focus on the environment, homelessness, health care, education, housing, and rebuilding San Francisco General Hospital.
Sources: en.wikipedia.org
Lately Executive Director, City Building. For services to Equality and Inclusion in Construction. Dr. Shriti Pattani. Lately President, The Society of Occupational Medicine. For services to Occupational Health. Nicola Heather Anne Patterson. Lately Director of Nursing, South Eastern Health and Social Care Trust. For services to Health and Social Care in Northern Ireland. Professor Rupert Mark Pearse. Professor of Intensive Care Medicine, Queen Mary University of London. For services to Intensive Care Medicine. Amy Sarah Perrin. Founder, The Marmalade Trust. For services to Older People. Oscar Victor Pinto-Hervia. Founder, Hervia. For services to Fashion and to Charity. Dr. Madsen Pirie. President, Adam Smith Institute. For services to Public Policy. Mary Margaret Portas. Retail Consultant and Broadcaster. For services to Business, to Broadcasting and to Charity. Alexander Reedijk. General Director, Scottish Opera. For services to the Performing Arts in Scotland. Marvin Rees. Mayor, Bristol City Council. For services to Local Government. Professor Julian Daryl Richards. Professor of Archaeology, University of York. For services to Heritage and Digital Archiving. Julian Richmond-Watson. Chair, Thoroughbred Breeders Association. For services to the British Horseracing Industry. José Salvador Riera. Deputy Director, Communications, Department for Culture, Media and Sport. For Public Service. Martin John Rigley, MBE. Lately Managing Director, Lindhurst Engineering Ltd. For services to the East Midlands Covid-19 Response and to the community in Derbyshire and Nottinghamshire.
== Accrediting organizations == For CLIA laboratories licensed under a Certificate of Accreditation (CoA), bi-annual inspections are conducted by a third-party accreditation organization (AO) that meets or exceeds the CLIA requirements. Though the Foundation for the Accreditation of Cellular Therapy (FACT) (formerly the Foundation for Accreditation of Hematopoietic Cell Transplantation) does not have deeming status under CLIA, most laboratories involved in cell therapies are accredited by FACT. In Dec 2022, TJC announced it would no longer recognize the Commission on Office Laboratory Accreditation (COLA) for lab accreditation at TJC hospitals, effective Jan 1, 2023, and facilities would have until Dec 31, 2024, to transition their accreditation. With the COVID-driven inspection backlog and a lack of inspectors, the move was criticized as being purely a financially driven attempt to capture additional market share. No reason for the change was given by CLIA, COLA, or TJC. TJC began recognizing COLA accreditation in 1997.
== External links == WHO fact sheet on opioid overdose Community management of opioid overdose (PDF). World Health Organization. 2014. ISBN 978-92-4-154881-6. Archived from the original (PDF) on 1 September 2022.
==== Come up ==== The "come up" phase can be defined as the period between the first noticeable changes in perception and the point of highest subjective intensity. This is colloquially known as "coming up."
Sources: en.wikipedia.org
The body is able to substantially reduce the amount of iron it absorbs across the mucosa. It does not seem to be able to entirely shut down the iron transport process. Also, in situations where excess iron damages the intestinal lining itself (for instance, when children eat a large quantity of iron tablets produced for adult consumption), even more iron can enter the bloodstream and cause a potentially deadly syndrome of iron overload. Large amounts of free iron in the circulation will cause damage to critical cells in the liver, the heart and other metabolically active organs. Iron toxicity results when the amount of circulating iron exceeds the amount of transferrin available to bind it, but the body is able to vigorously regulate its iron uptake. Thus, iron toxicity from ingestion is usually the result of extraordinary circumstances like iron tablet over-consumption[1] rather than variations in diet. The type of acute toxicity from iron ingestion causes severe mucosal damage in the gastrointestinal tract, among other problems. Excess iron has been linked to higher rates of disease and mortality. For example, breast cancer patients with low ferroportin expression (leading to higher concentrations of intracellular iron) survive for a shorter period of time on average, while high ferroportin expression predicts 90% 10-year survival in breast cancer patients. Similarly, genetic variations in iron transporter genes known to increase serum iron levels also reduce lifespan and the average number of years spent in good health.
=== Ka--Kj === Henri B. Kagan (born 1930) French chemist, pioneer of asymmetric catalysis, 2001 Wolf Prize in Chemistry Isabella Karle (1921–2017), American chemist instrumental for extracting plutonium chloride from a mixture containing plutonium oxide Jerome Karle (1918–2013), 1985 Nobel Prize in Chemistry for the direct analysis of crystal structures by X-ray scattering Paul Karrer (1889–1971), Swiss organic chemist known for research on vitamins, 1937 Nobel Prize in Chemistry Alan R. Katritzky (1928–2014), British-American organic chemist, pioneer of heterocyclic chemistry Joyce Jacobson Kaufman (1929–2016), American chemist and inventor of conformational topology Melinda H. Keefe (PhD 2001), American chemist known for identifying solvents that can be used to remove dirt without damaging layers of paint August Kekulé (1829–1896), German organic chemist known for the theory of chemical structure, especially the structure of benzene John Kendrew (1917–1997), British biochemist and crystallographer known for solving the structure of myoglobin, 1962 Nobel Prize in Chemistry Ann Kiessling (born 1942), American chemist and reproductive biologist known for discovering reverse transcriptase activity in normal human cells Ann Kimble-Hill (21st century), American biochemist studying structure-function relationships of membrane proteins and lipids Petrus Jacobus Kipp (1808–1864), Dutch chemist, inventor of Kipp's apparatus Johan Kjeldahl (1849–1900), Danish chemist who developed a method for determining the amount of nitrogen in organic compounds
Downtown Emergency Service Center (DESC), in Seattle, Washington, operates several Housing First programmes which utilize the harm reduction model. University of Washington researchers, partnering with DESC, found that providing housing and support services for homeless alcoholics costs taxpayers less than leaving them on the street, where taxpayer money goes towards police and emergency health care. Results of the study funded by the Substance Abuse Policy Research Program (SAPRP) of the Robert Wood Johnson Foundation appeared in the Journal of the American Medical Association in April 2009. This first controlled assessment in the U.S. of the effectiveness of Housing First, specifically targeting chronically homeless alcoholics, showed that the programme saved taxpayers more than $4 million over the first year of operation. During the first six months, the study reported an average cost-savings of 53 percent (even after considering the cost of administering the housing's 95 residents)—nearly $2,500 per month per person in health and social services, compared to the per month costs of a wait-list control group of 39 homeless people. Further, despite the fact residents are not required to be abstinent or in treatment for alcohol use, stable housing also results in reduced drinking among people experiencing homelessness who recreationally use alcohol.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.